View Older Stories View More Recent Stories

Sep 3, 2019 05:51AM AstraZeneca (AZN) Reports Detailed Results from Ph. III DAPA-HF Trial Showed FARXIGA Significantly Reduced Both Incidence of Cardiovascular Death & Worsening of Heart Failure
Sep 1, 2019 09:15AM BRILINTA Reduced the Risk of Cardiovascular Events in Patients With Coronary Artery Disease and Type 2 Diabetes in Phase III THEMIS Trial
Sep 1, 2019 08:35AM Detailed Results from Phase III DAPA-HF Trial Showed FARXIGA Significantly Reduced Both the Incidence of Cardiovascular Death and the Worsening of Heart Failure
Aug 28, 2019 07:01AM AstraZeneca (AZN) Reports T010 Phase III ETHOS Trial Met its Primary Endpoint in Chronic Obstructive Pulmonary Disease
Aug 28, 2019 07:00AM PT010 Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease
Aug 27, 2019 07:00AM FDA Grants Fast Track Designation for FARXIGA in Chronic Kidney Disease
Aug 20, 2019 07:10AM AstraZeneca (AZN) Reports FARXIGA Met Primary Endpoint in Landmark Phase III DAPA-HF Trial
Aug 20, 2019 07:00AM FARXIGA Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients With Heart Failure
Aug 14, 2019 08:06AM AstraZeneca (AZN) Reports CALQUENCE (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia
Aug 14, 2019 08:00AM CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia
Aug 14, 2019 07:00AM LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer
Aug 9, 2019 07:00AM TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer
Aug 7, 2019 06:55AM LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint
Jul 22, 2019 08:03AM AstraZeneca (AZN) Reports IMFINZI US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer
Jul 22, 2019 08:00AM IMFINZI® (durvalumab) US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer
Jul 1, 2019 03:30PM Foundation Medicine Expands Indication for FoundationOne®CDx as a Companion Diagnostic for LYNPARZA® (Olaparib)
Jun 27, 2019 08:57AM AstraZeneca (AZN) Announces IMFINZI Improves OS at Interim Analysis in Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer
Jun 27, 2019 08:56AM IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer
Jun 19, 2019 06:48AM AstraZeneca (AZN) and Merck's LYNPARZA Approved in Japan as First-Line Maintenance Therapy in Patients with BRCAm Advanced Ovarian Cancer
Jun 17, 2019 06:16AM AstraZeneca (AZN) Reports Detailed Results from Interim Analysis of Phase 3 ASCEND Trial at EHA 2019 Meetings
Jun 15, 2019 07:00AM CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
Jun 14, 2019 07:00AM LOKELMA™ Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis
Jun 10, 2019 08:04AM AstraZeneca (AZN) Announces FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type
Jun 10, 2019 08:00AM FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes
Jun 3, 2019 06:04AM Merck (MRK), AstraZeneca (AZN) Report Results from Phase 3 POLO trial evaluating LYNPARZA as First-Line Maintenance Therapy
Jun 2, 2019 09:00AM IMFINZI® (Durvalumab) is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer
May 22, 2019 07:00AM Bob Harper and AstraZeneca Expand Survivors Have Heart Initiative to Empower and Unite Heart Attack Survivors Nationwide
May 20, 2019 08:12AM AstraZeneca (AZN) announces FASENRA reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthma
May 20, 2019 08:00AM FASENRA® (benralizumab) reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthma
May 16, 2019 08:00AM AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting
May 8, 2019 07:00AM AstraZeneca Teams Up with PGA Golf Champion Jason Day to Raise Awareness about the Importance of Biomarker Testing in Lung Cancer
May 3, 2019 09:00AM Change Makers Across the Oncology Community Recognized at 2019 Cancer Community (C2) Awards
Apr 10, 2019 06:46AM AstraZeneca (AZN) and Merck's (MRK) LYNPARZA Approved in EU for Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer
Apr 4, 2019 07:08AM Myriad Genetics (MYGN), AstraZeneca (AZN) and Merck (MRK) Expand Companion Diagnostic Partnership
Apr 1, 2019 06:34AM AstraZeneca (AZN) and Merck (MRK) Announce Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1
Apr 1, 2019 06:30AM Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1
Mar 18, 2019 09:01AM First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes
Mar 11, 2019 08:00AM AstraZeneca to Present New Cardiovascular Data on FARXIGA in Type 2 Diabetes At ACC 2019
Feb 27, 2019 08:06AM AstraZeneca (AZN) Announces FDA Approved Expanded FARXIGA and XIGDUO XR Labels for Use in Patients with Type 2 Diabetes and Moderate Renal Impairment
Feb 27, 2019 08:00AM US FDA Approves Expanded FARXIGA and XIGDUO XR Labels for Use in Patients with Type 2 Diabetes and Moderate Renal Impairment
Feb 26, 2019 06:56AM Merck (MRK), AstraZeneca (AZN) Say LYNPARZA Reduced Risk of Disease Progression or Death as First-Line Maintenance Treatment in gBRCAm
Feb 26, 2019 06:55AM LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as 1st-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer
Feb 25, 2019 07:00AM BRILINTA’s Phase III THEMIS Trial Met Primary Endpoint in Patients with Established Coronary Artery Disease and Type-2 Diabetes
Dec 20, 2018 07:09AM AstraZeneca (AZN) Announces Phase III OLYMPUS and ROCKIES Trials for roxadustat Met Their Primary Endpoints in Chronic Kidney Disease Patients With Anemia
Dec 20, 2018 07:00AM Phase III OLYMPUS and ROCKIES Trials for roxadustat Met Their Primary Endpoints in Chronic Kidney Disease Patients With Anemia
Dec 19, 2018 04:04PM AstraZeneca (AZN) and Merck (MRK) Reports LYNPARZA Approved by FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer
Dec 19, 2018 04:01PM LYNPARZA® (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer
Dec 3, 2018 01:45PM New Long-Term Data on CALQUENCE Presented at ASH 2018
Nov 27, 2018 07:00AM AstraZeneca Presents Clinical Research Advances for Blood Cancer Patients at 2018 American Society of Hematology Annual Meeting
Nov 12, 2018 06:55AM US FDA Accepts Regulatory Submission For LYNPARZA (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review
View More Recent Stories View Older Stories